[go: up one dir, main page]

AR099466A1 - Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina - Google Patents

Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina

Info

Publication number
AR099466A1
AR099466A1 ARP150100403A ARP150100403A AR099466A1 AR 099466 A1 AR099466 A1 AR 099466A1 AR P150100403 A ARP150100403 A AR P150100403A AR P150100403 A ARP150100403 A AR P150100403A AR 099466 A1 AR099466 A1 AR 099466A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
methyl
independently selected
disorder
Prior art date
Application number
ARP150100403A
Other languages
English (en)
Inventor
Nguyen William
Song Xinyi
Jason Herr Robert
Barnes Keith
D Young Steven
Jiang Qin
M Kamenecka Theodore
He Yuanjun
Jiang Rong
Original Assignee
Eolas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eolas Therapeutics Inc filed Critical Eolas Therapeutics Inc
Publication of AR099466A1 publication Critical patent/AR099466A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente hace referencia a compuestos que modulan la bioactividad de un receptor de orexina como por ejemplo OX₁ o OX₂, o ambos; a composiciones farmacéuticas y combinaciones que comprenden un compuesto de la presente; a métodos de tratamiento de afecciones en pacientes para las cuales se indica médicamente la modulación de un receptor de orexina; y a métodos de preparación de compuestos de la presente. Por ejemplo, los compuestos moduladores del receptor de orexina de la presente pueden usarse en el tratamiento de un trastorno de la alimentación, obesidad, alcoholismo o un trastorno relacionado con el alcohol, abuso de sustancias o adicción a las mismas incluyendo adicción a cocaína, opiáceos, anfetaminas o nicotina, un trastorno del sueño, una disfunción cognitiva en un trastorno psiquiátrico o neurológico, depresión, ansiedad, trastorno de estrés postraumático, trastorno afectivo estacional, un trastorno de la alimentación, trastorno de pánico, esquizofrenia, enfermedad de Alzheimer, enfermedad de Parkinson, corea de Huntington, dolor de cabeza, migraña, dolor, enfermedades gastrointestinales, epilepsia, inflamaciones, enfermedades relacionadas con el sistema inmune, enfermedades relacionadas con el sistema endocrino, cáncer, hipertensión, trastornos del comportamiento, trastornos anímicos, depresión con manía, demencia, trastornos sexuales, trastornos psicosexuales, o enfermedad renal. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) donde R¹⁰ es H o metilo; Het² se selecciona entre el grupo que consiste en pirrolilo, pirazolilo, imidazolilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, pirimidinilo, piridazinilo y pirazinilo; donde Het² está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados en forma independiente entre el grupo que consiste en halo, C₁₋₄alquilo, C₁₋₄alcoxi, -CN, -CF₃, y C₃₋₆cicloalquilo, donde dicho cicloalquilo está opcionalmente sustituido con halo, metilo, o ciano; o dos sustituyentes adyacentes tomados junto con los átomos a los que están unidos forman un fenilo fusionado o heteroarilo monocíclico; X, Y, y Z se definen como en (a), (b), o (c), donde: (a) X es N, Y es CH, y Z es S; (b) X es N, Y es CHCH, y Z es CH; y (c) X es CH, Y es CHCH, y Z es CH; donde los grupos CH están opcionalmente sustituidos con B y (R¹¹)ₜ como se muestra; cada R¹¹ se selecciona en forma independiente entre el grupo que consiste en metilo, ciano, cloro, fluoro, y metoxi; t es 0, 1, ó 2; y B se selecciona entre el grupo que consiste en fenilo, pirrolilo, pirazolilo, imidazolilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, pirimidinilo, piridazinilo y pirazinilo, cada uno de ellos opcionalmente sustituido con uno o dos sustituyentes Rʸ; en donde Rʸ se selecciona en forma independiente entre el grupo que consiste en metilo, etilo, propilo, isopropilo, butilo, isobutilo, metoxi, etoxi, isopropoxi, -F, -Cl, -Br, -CN, y CF₃; o una sal farmacéuticamente aceptable del mismo; siempre que el compuesto no sea de fórmula (2); o un compuesto de fórmula (3) donde R¹⁰ es H o metilo; Het² se selecciona entre el grupo que consiste en pirrolilo, pirazolilo, imidazolilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, pirimidinilo, piridazinilo y pirazinilo; donde Het² está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados en forma independiente entre el grupo que consiste en halo, C₁₋₄alquilo, C₁₋₄alcoxi, -CN, -CF₃, y C₃₋₆cicloalquilo, donde dicho cicloalquilo está opcionalmente sustituido con halo, metilo, o ciano; o dos sustituyentes adyacentes tomados junto con los átomos a los que están unidos forman un fenilo fusionado o heteroarilo monocíclico; X, Y, y Z se definen como en (a), (b), o (c), donde: (a) X es N, Y es CH, y Z es S; (b) X es N, Y es CHCH, y Z es CH; y (c) X es CH, Y es CHCH, y Z es CH; donde los grupos CH están opcionalmente sustituidos con B y (R¹¹)ₜ como se muestra; cada R¹¹ se selecciona en forma independiente entre el grupo que consiste en metilo, ciano, cloro, fluoro, y metoxi; t es 0, 1, ó 2; y B se selecciona entre el grupo que consiste en fenilo, pirrolilo, pirazolilo, imidazolilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, pirimidinilo, piridazinilo y pirazinilo, cada uno de ellos opcionalmente sustituido con uno o dos sustituyentes Rʸ; en donde Rʸ se selecciona en forma independiente entre el grupo que consiste en metilo, etilo, propilo, isopropilo, butilo, isobutilo, metoxi, etoxi, isopropoxi, -F, -Cl, -Br, -CN, y CF₃; o una sal farmacéuticamente aceptable del mismo; o un compuesto de fórmula (4) donde Het² se selecciona entre el grupo que consiste en pirrolilo, pirazolilo, imidazolilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, pirimidinilo, piridazinilo y pirazinilo; donde Het² está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados en forma independiente entre el grupo que consiste en halo, C₁₋₄alquilo, C₁₋₄alcoxi, -CN, -CF₃, y C₃₋₆cicloalquilo, donde dicho cicloalquilo está opcionalmente sustituido con halo, metilo, o ciano; o dos sustituyentes adyacentes tomados junto con los átomos a los que están unidos forman un fenilo fusionado o heteroarilo monocíclico; X, Y, y Z se definen como en (a), (b), o (c), donde: (a) X es N, Y es CH, y Z es S; (b) X es N, Y es CHCH, y Z es CH; y (c) X es CH, Y es CHCH, y Z es CH; donde los grupos CH están opcionalmente sustituidos con B y (R¹¹)ₜ como se muestra; cada R¹¹ se selecciona en forma independiente entre el grupo que consiste en metilo, ciano, cloro, fluoro, y metoxi; t es 0, 1, ó 2; y B se selecciona entre el grupo que consiste en fenilo, pirrolilo, pirazolilo, imidazolilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, pirimidinilo, piridazinilo y pirazinilo, cada uno de ellos opcionalmente sustituido con uno o dos sustituyentes Rʸ; en donde Rʸ se selecciona en forma independiente entre el grupo que consiste en metilo, etilo, propilo, isopropilo, butilo, isobutilo, metoxi, etoxi, isopropoxi, -F, -Cl, -Br, -CN, y CF₃; o una sal farmacéuticamente aceptable del mismo.
ARP150100403A 2012-02-07 2015-02-11 Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina AR099466A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596062P 2012-02-07 2012-02-07
US14/179,432 US9499517B2 (en) 2012-02-07 2014-02-12 Substituted prolines / piperidines as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
AR099466A1 true AR099466A1 (es) 2016-07-27

Family

ID=48947950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100403A AR099466A1 (es) 2012-02-07 2015-02-11 Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina

Country Status (18)

Country Link
US (2) US9499517B2 (es)
EP (1) EP2811997B1 (es)
JP (1) JP6346862B2 (es)
KR (1) KR20140124398A (es)
CN (1) CN104220065A (es)
AR (1) AR099466A1 (es)
AU (1) AU2013217323A1 (es)
BR (1) BR112014019426A8 (es)
CA (1) CA2863413A1 (es)
ES (1) ES2672732T3 (es)
HK (1) HK1204955A1 (es)
IL (1) IL234025A0 (es)
MX (1) MX2014009281A (es)
NZ (1) NZ628491A (es)
PH (1) PH12014501784A1 (es)
RU (1) RU2014136339A (es)
SG (1) SG11201404738QA (es)
WO (1) WO2013119639A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653263B2 (en) 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ES2672732T3 (es) 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
ITMI20120322A1 (it) * 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
WO2014085208A1 (en) * 2012-11-27 2014-06-05 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
WO2015018027A1 (en) * 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Thiazole orexin receptor antagonists
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
WO2015123355A1 (en) * 2014-02-12 2015-08-20 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
UY36272A (es) * 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
EP3191468B1 (en) * 2014-09-11 2018-12-12 Janssen Pharmaceutica NV Substituted 2-azabicycles and their use as orexin receptor modulators
JP2018016544A (ja) * 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ［２．２．２］オクタン誘導体
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
TWI710557B (zh) * 2016-02-12 2020-11-21 美商伊歐拉斯治療學公司 作為食慾素受體調節劑之經鹵素取代之六氫吡啶
BR112018067906A2 (pt) 2016-03-10 2019-01-29 Janssen Pharmaceutica Nv métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
RU2738646C2 (ru) * 2016-04-01 2020-12-15 РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС Модуляторы эстрогеновых рецепторов
CN109640998A (zh) * 2016-05-12 2019-04-16 卫材研究发展管理有限公司 治疗昼夜节律性睡眠障碍的方法
MD3676261T2 (ro) * 2017-09-01 2025-05-31 Chronos Therapeutics Ltd 2-azabiciclo[3.1.1]heptan substituit și derivați de 2-azabiciclo[3.2.1]octan ca antagoniști ai receptoriului orexinei
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
US12187737B2 (en) 2019-06-04 2025-01-07 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
SG11202112828SA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
EP4353309A4 (en) * 2021-05-26 2025-05-07 Sumitomo Pharma Co., Ltd. PHENYLUREA DERIVATIVE

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049578A (en) * 1990-03-09 1991-09-17 E. R. Squibb & Sons, Inc. 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
DE69906960T2 (de) 1998-05-08 2004-01-29 Smithkline Beecham Plc Phenylurea und phenylthio urea derivate
ES2226785T3 (es) 1999-02-12 2005-04-01 Smithkline Beecham Plc Derivados de fenilurea como antagonistas de los receptores de orexina.
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
AU2910600A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives
CA2374793A1 (en) 1999-05-24 2000-11-30 Penglie Zhang Inhibitors of factor xa
WO2001085693A1 (en) 2000-05-11 2001-11-15 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
EP1289955B1 (en) * 2000-06-16 2005-04-13 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
WO2002090355A1 (en) * 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amines
US20040192673A1 (en) 2001-05-05 2004-09-30 Pascale Gaillard N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
CN1556705B (zh) 2002-07-09 2010-04-28 埃科特莱茵药品有限公司 7,8,9,10-四氢-6H-氮杂卓并、6,7,8,9-四氢-吡啶并和2,3-二氢-2H-吡咯并[2,1-b]-喹唑啉酮衍生物
WO2004026866A1 (en) * 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
KR20050043988A (ko) 2002-10-11 2005-05-11 액테리온 파마슈티칼 리미티드 설포닐아미노-아세트산 유도체 및 오렉신 수용체길항제로서 이들의 용도
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
US6951882B2 (en) 2002-12-12 2005-10-04 Janssen Pharmaceutica N.V. Substituted 4-phenyl-[1,3]-dioxanes
CN100432056C (zh) 2003-03-26 2008-11-12 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
WO2004096780A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Quinoxalinone-3- one derivatives as orexin receptor antagonists
HUP0304101A3 (en) 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
WO2006067224A2 (en) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
JP2008538361A (ja) 2005-04-12 2008-10-23 メルク エンド カムパニー インコーポレーテッド アミドプロポキシフェニルオレキシン受容体アンタゴニスト
EP1885892A2 (en) 2005-05-03 2008-02-13 Ensemble Discovery Corporation Turnover probes and use thereof for nucleic acid detection
CA2609203A1 (en) 2005-05-23 2006-11-30 Merck & Co., Inc Proline bis-amide orexin receptor antagonists
US20090258903A1 (en) 2005-08-04 2009-10-15 Coleman Paul J Aminoethane Sulfonamide Orexin Receptor Antagonists
WO2007025069A2 (en) 2005-08-26 2007-03-01 Merck & Co., Inc. Diazaspirodecane orexin receptor antagonists
EP1954276A2 (en) 2005-11-22 2008-08-13 Merck & Co., Inc. Indole orexin receptor antagonists
CN101009515A (zh) 2006-01-24 2007-08-01 华为技术有限公司 通信终端设备管理方法及通信终端
TW200800020A (en) * 2006-01-26 2008-01-01 Basf Ag Methods to use 3-pyridyl derivatives as pesticides
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
US20090105318A1 (en) 2006-03-29 2009-04-23 Coleman Paul J Amidoethylthioether Orexin Receptor Antagonists
EP2007717A1 (en) 2006-04-11 2008-12-31 Actelion Pharmaceuticals Ltd. Novel sulfonamide compounds
CN101432285A (zh) 2006-04-26 2009-05-13 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的吡唑并-四氢吡啶衍生物
WO2007143813A1 (en) 2006-06-16 2007-12-21 Husky Injection Molding Systems Ltd. Preventative maintenance update system
AU2007272855B2 (en) 2006-07-14 2013-08-01 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
AU2007272795A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
US7994336B2 (en) 2006-08-15 2011-08-09 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
DE602007004999D1 (de) 2006-08-28 2010-04-08 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
CL2007002809A1 (es) * 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
US8133901B2 (en) 2006-12-01 2012-03-13 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
BRPI0720522A2 (pt) 2006-12-22 2014-01-07 Actelion Pharmaceuticals Ltd Composto derivado de 5,6,7,8-tetra-hidroimidazo [1,5-a] pirazina e uso deste ou de um de seus sais farmaceuticamente aceitáveis.
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008087611A2 (en) * 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
JP2010520206A (ja) 2007-03-02 2010-06-10 メルク・シャープ・エンド・ドーム・コーポレイション ビピリジンカルボキサミドオレキシン受容体アンタゴニスト
JP5138708B2 (ja) 2007-03-05 2013-02-06 エフ．ホフマン−ラ ロシュ アーゲー オレキシンアンタゴニストとしてのアミノアミド
WO2008110488A1 (en) 2007-03-15 2008-09-18 F. Hoffmann-La Roche Ag Malonamides as orexin antagonists
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
ES2365444T3 (es) 2007-04-04 2011-10-05 F. Hoffmann-La Roche Ag Heterociclos como antagonistas de orexina.
JP2010526869A (ja) 2007-05-14 2010-08-05 アクテリオン ファーマシューティカルズ リミテッド ２−シクロプロピル−チアゾール誘導体
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
AU2008257411B2 (en) 2007-05-23 2012-04-26 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
JP2010528007A (ja) * 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
US8106215B2 (en) * 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
US8288429B2 (en) 2007-07-27 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.3.0]octane derivatives
WO2009016560A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
BRPI0814767A2 (pt) 2007-08-02 2015-03-03 Hoffmann La Roche Derivados de monoamida como antagonistas do receptor de orexina
WO2009020642A1 (en) 2007-08-09 2009-02-12 Merck & Co., Inc. Pyridine carboxamide orexin receptor antagonists
CA2702292A1 (en) * 2007-08-10 2009-02-19 Rudolf Mueller Bicyclic amides for ehancing glutamatergic synaptic responses
MX2010001575A (es) 2007-08-15 2010-03-15 Actelion Pharmaceuticals Ltd Derivados de 1,2-diamido-etileno como antagonistas de orexina.
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
US8362009B2 (en) 2007-10-29 2013-01-29 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
EP2231155A4 (en) 2007-12-18 2011-09-14 Concert Pharmaceuticals Inc Tetrahydroisoquinoline DERIVATIVES
CN101903372B (zh) 2007-12-21 2014-06-18 弗·哈夫曼-拉罗切有限公司 作为食欲肽受体拮抗剂的杂芳基衍生物
EP2245006B1 (en) 2008-01-21 2011-06-01 F. Hoffmann-La Roche AG Sulfonamides as orexin antagonists
WO2009100994A1 (en) 2008-02-12 2009-08-20 F. Hoffmann-La Roche Ag Piperidine sulfonamide derivatives
WO2009104155A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
US20110086889A1 (en) 2008-06-11 2011-04-14 Hamed Aissaoui Tetrazole compounds as orexin receptor antagonists
WO2009153180A1 (en) 2008-06-16 2009-12-23 F. Hoffmann-La Roche Ag Heteroaromatic monoamides as orexinin receptor antagonists
EP2307417A2 (en) 2008-06-25 2011-04-13 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
CN102083827A (zh) 2008-07-07 2011-06-01 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的噻唑烷化合物
KR101359852B1 (ko) 2008-07-29 2014-02-06 에프. 호프만-라 로슈 아게 오렉신 길항제로서 피롤리딘-3-일메틸-아민
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
CN102164896A (zh) 2008-10-14 2011-08-24 埃科特莱茵药品有限公司 苯乙基酰胺衍生物及其杂环类似物
WO2010048010A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2350061B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
US8623863B2 (en) 2008-10-21 2014-01-07 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
CA2739919A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
CA2739917A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
EP2349269A4 (en) 2008-10-21 2012-04-25 Merck Sharp & Dohme 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
CA2741648A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
BRPI0919876A8 (pt) 2008-10-30 2016-02-10 Merck Sharp & Dohme Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
WO2010051238A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
UY32277A (es) 2008-12-02 2010-05-31 Glaxo Group Ltd Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos
JP2010155827A (ja) 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
UY32404A (es) 2009-01-30 2010-08-31 Novartis Ag 4-aril-butan-1,3-diamidas
MX2011011127A (es) 2009-04-24 2011-11-18 Glaxo Group Ltd 3-azabiciclo[4.1.0] heptanos usados como antagonistas de orexina.
US20120101106A1 (en) 2009-07-09 2012-04-26 Mercer Swati P Tetrahydronapthyridine Orexin Receptor Antagonists
EP2275421A1 (en) 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
US8809380B2 (en) * 2009-08-04 2014-08-19 Raqualia Pharma Inc. Picolinamide derivatives as TTX-S blockers
WO2011023578A1 (en) * 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
US20120149711A1 (en) * 2009-08-24 2012-06-14 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US8653263B2 (en) 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US20120196901A1 (en) 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
US20120258957A1 (en) 2009-11-23 2012-10-11 Matilda Jane Bingham Heterocyclic derivatives
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
AR079553A1 (es) 2009-12-21 2012-02-01 Novartis Ag Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
JP2013515032A (ja) 2009-12-21 2013-05-02 ノバルティス アーゲー 二置換ヘテロアリール縮合ピリジン類
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2011138266A1 (en) 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
TW201307320A (zh) 2010-12-17 2013-02-16 大正製藥股份有限公司 吡唑衍生物
US20120165331A1 (en) 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
JP5987005B2 (ja) 2011-02-18 2016-09-06 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン拮抗薬として有用な新規なピラゾール及びイミダゾール誘導体
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
JPWO2012153729A1 (ja) 2011-05-10 2014-07-31 大正製薬株式会社 ヘテロ芳香環誘導体
WO2013005755A1 (ja) 2011-07-05 2013-01-10 大正製薬株式会社 メチルピペリジン誘導体
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013059163A1 (en) 2011-10-21 2013-04-25 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
US8940898B2 (en) 2011-10-25 2015-01-27 Merck Sharp & Dohme Corp. Piperidinyl alkyne orexin receptor antagonists
US9242995B2 (en) 2011-10-25 2016-01-26 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
KR101676930B1 (ko) 2011-11-08 2016-11-16 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 ２-(１,２,３-트리아졸-２-일)벤즈아미드 및 ３-(１,２,３-트리아졸-２-일)피콜린아미드 유도체
ITMI20112329A1 (it) 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
ES2672732T3 (es) * 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2013123240A1 (en) 2012-02-17 2013-08-22 Eisai R&D Management Co., Ltd Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
ITMI20120322A1 (it) 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
WO2015123355A1 (en) 2014-02-12 2015-08-20 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists

Also Published As

Publication number Publication date
RU2014136339A (ru) 2016-03-27
MX2014009281A (es) 2015-01-12
US20140364432A1 (en) 2014-12-11
CA2863413A1 (en) 2013-08-15
KR20140124398A (ko) 2014-10-24
EP2811997B1 (en) 2018-04-11
IL234025A0 (en) 2014-09-30
JP6346862B2 (ja) 2018-06-20
PH12014501784A1 (en) 2014-11-10
US9896452B2 (en) 2018-02-20
JP2015506382A (ja) 2015-03-02
US20170101410A1 (en) 2017-04-13
NZ628491A (en) 2016-06-24
BR112014019426A2 (es) 2017-06-20
AU2013217323A1 (en) 2014-08-28
HK1204955A1 (zh) 2015-12-11
BR112014019426A8 (pt) 2017-07-11
EP2811997A4 (en) 2015-07-22
US9499517B2 (en) 2016-11-22
ES2672732T3 (es) 2018-06-15
CN104220065A (zh) 2014-12-17
EP2811997A1 (en) 2014-12-17
WO2013119639A1 (en) 2013-08-15
SG11201404738QA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
AR099466A1 (es) Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina
AR121661A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
RU2018130727A (ru) Органические соединения
JP2015506382A5 (es)
CN102316931B (zh) 烷基氨基化合物和其用途
Fleuren et al. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
RU2010126622A (ru) Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10
JP2010538001A5 (es)
JP2008524328A5 (es)
MA31571B1 (fr) Composes organiques
CR11554A (es) Pirrolo-Pirimidinas y Pirrolo-Piridinas
JP2012508223A5 (es)
AR058326A1 (es) Anticuerpo monoclonal
AR101177A1 (es) Inhibidores de la syk
TW201613891A (en) Substituted prolines / piperidines as orexin receptor antagonists
AR087628A1 (es) Inhibidores de pde10 de pirimidina
WO2017025814A1 (en) Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
JP2014503576A5 (es)
WO2009039431A3 (en) Substituted aryl-fused spirocyclic amines
CN103080107A (zh) 作为蛋白激酶抑制剂的杂芳基化合物和组合物
JP2016516774A5 (es)
JP2021508318A (ja) チューブリン阻害剤
JP2017508795A5 (es)
RU2017115726A (ru) Ингибиторы лизин-специфичного гингипаина
HRP20211156T1 (hr) Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina

Legal Events

Date Code Title Description
FB Suspension of granting procedure